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Background/aim: The aim of this study was to report the gestational age (GA) and birth weight (BW) distribution of premature babies
who needed treatment for retinopathy of prematurity (ROP) and to assess the timing of the treatment.
Materials and methods: The records of 9008 infants who were screened for ROP were examined and 556 infants who underwent laser
therapy for ROP were reviewed. Sex, GA, BW, postnatal age, and postmenstrual (PM) age at the time of laser therapy were recorded. The
babies were classified as in-born (Group 1) and out-born infants (Group 2).
Results: The mean GA was 27.3 weeks (range: 22–33 weeks) and the mean BW was 991.1 g (range: 520–2160 g). Of the treated infants,
7.0% were born later than 32 weeks and 8.3% were born over 1500 g. The mean postnatal age was 9.48 weeks (range: 5–22 weeks) and
the mean PM age was 36.72 weeks (range: 29–48 weeks) at the time of treatment. Mean BWs and GAs were significantly higher and the
mean postnatal age at the time of laser therapy was significantly earlier in Group 2.
Conclusion: Infants with severe ROP had a wider range of BWs and GAs compared to those from developed countries and earlier
treatment was needed for out-born infants.
Key words: Laser photocoagulation, retinopathy of prematurity, screening

1. Introduction
Advances in neonatal care and increasing survival rates
have been associated with an increasing number of
prematurely born infants. Retinopathy of prematurity
(ROP) continues to be an important cause of childhood
blindness all over the world. The clinical features of
infants developing severe ROP vary among developed and
developing countries (1–4).
Revised ROP screening guidelines by the American
Academy of Ophthalmology, the American Academy of
Pediatrics, and the American Association for Pediatric
Ophthalmology and Strabismus suggest screening all
infants with a birth weight (BW) of 1500 g or less and/
or a gestational age (GA) of 30 weeks or less and selected
infants with a BW between 1500 and 2000 g or a GA of
over 30 weeks with an unstable clinical course, including
those requiring cardiorespiratory support and who are
believed by their attending neonatologist or pediatrician to
be at high risk for ROP (5). The UK guideline recommends
screening all infants with a GA of less than 30 weeks or
* Correspondence: zuhaltunay@gmail.com
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with a BW of less than 1251 g (6). The recommended age
for the initial ROP examination is 4–6 postnatal weeks or
31 PM weeks (5–7). These guidelines are based on studies
that showed that the development of severe ROP requiring
treatment is rare in infants with a BW over 1250 g and/or
a GA greater than 31 weeks (5–8). In developing low- and
middle-income countries, ROP has been reported in older
and/or larger infants (9).
In this study, we had four objectives: to report the
BW and GA distribution of premature infants who were
treated with laser photocoagulation for severe ROP and
to determine the population at risk for severe ROP in our
country; to assess the timing of the treatment; to evaluate
the appropriateness of the ROP screening criteria for our
clinic, which is a referral center for ROP in our country;
and to contribute to a subsequent metaanalysis.
2. Materials and methods
A hospital-based retrospective study of premature neonates
who were screened for ROP between January 2006 and
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December 2013 was conducted. The data were collected
from prospectively completed ROP screening forms and
retrospectively analyzed by the authors. All infants with a
BW of 1500 g or less and/or a GA of 32 weeks or less, and
selected infants with a BW of over 1500 g or a GA of more
than 32 weeks with an unstable clinical course (as defined
by the attending neonatologist or pediatrician), were
screened. Infants with systemic anomalies and/or with
ocular anomalies, such as microphthalmia, anophthalmia,
coloboma, or congenital cataracts in one or both eyes,
or those who died during the follow-up period or were
unavailable for follow-up were excluded from the study.
The first examination was performed at 4 postnatal weeks
for all infants and the infants continued to be monitored
until complete retinal vascularization was reached.
The medical records of 9008 infants who underwent
screening examination for ROP were reviewed and 556
patients who underwent laser photocoagulation therapy
for severe ROP were examined in this study. Sex, BW,
GA, postnatal age, and PM age at the time of treatment
were analyzed. The need for treatment was based on the
Early Treatment of ROP (ETROP) criteria and all infants
underwent transpupillary laser photocoagulation therapy
with an 810-nm diode laser delivered through the indirect
ophthalmoscopic system under general anesthesia (8).
The annual distribution of the patients was examined and
changes according to years were evaluated. The treated
patients were classified as in-born infants (Group 1: infants
who were born in our hospital and who received treatment
for ROP in our hospital) and out-born infants (Group 2:
infants who were born at different centers and referred to
our hospital for ROP treatment). The variables regarding
BW, GA, PM, and postnatal age at the time of laser therapy
were compared independently between these groups.
SPSS 16.0 was used for statistical analysis. Descriptive
statistics were given as mean ± standard deviation (SD)
and percentages. An independent sample t-test was used

for comparisons between groups. P < 0.05 was considered
significant.
The study was approved by the hospital ethics
committee and informed written consent was obtained
from the parents or guardians before enrollment. All
works were conducted in accordance with the Declaration
of Helsinki and with the approval of the institutional
review board.
3. Results
Of the 9008 infants screened, 556 (6.2%) were treated with
laser photocoagulation according to ETROP criteria. Of
the 556 infants representing the original cohort, 396 (71%)
infants were in Group 1 and 160 (29%) were in Group
2. The number of treatment-requiring severe ROP cases
decreased from 6.2% to 4.5% when the infants in Group 2
were excluded.
Two hundred and sixty (46.8%) infants were female
and 296 (53.2%) were male. The mean GA was 27.3 ± 2.5
weeks (range: 22–33 weeks) and the median GA was 27
weeks. The mean BW was 991.1 ± 314.7 g (range: 520–
2160 g). Of the treated infants, 39 (7.0%) were born at
a GA of 32 weeks and no infant was born later than 33
weeks. Forty-six infants (8.3%) were born over 1500 g
and 20 (3.6%) over 1750 g. Only three infants had BWs
over 2000 g and the highest BW was 2160 g. Tables 1 and
2 display the distribution of the treated infants according
to BW and GA. The annual distributions of the examined
and the treated infants are analyzed by the means of BW
and GA in Table 3.
The mean postnatal age at the time of laser treatment
was 9.48 ± 2.82 weeks (range: 5–22 weeks) and the mean
PM age at the time of treatment was 36.72 ± 2.83 weeks
(range: 29–48 weeks). Treatment was needed at 5 postnatal
weeks for 14 infants (2.5%) and at 6 postnatal weeks for 66
(11.9%) infants. When we analyzed PM ages at the time of
treatment, treatments were needed before 31 PM weeks for
four infants. Eleven (2.0%) infants were over 42 PM weeks

Table 1. The distribution of treated infants in relation to birth weight.
Birth weight (g)

Number of treated infants

%

<750

144

25.9

751–1000

202

36.3

1001–1250

120

21.6

1251–1500

44

7.9

1501–1750

26

4.7

>1750

20

3.6

Total

556

100.0

43

ÖZEN TUNAY et al. / Turk J Med Sci
Table 2. The distribution of treated infants in relation to GA.
Gestational age (weeks)

Number of treated infants

%

<26

134

24.1

26–28

269

48.4

29–31

112

20.1

≥32

41

7.4

Total

556

100.0

Table 3. The annual distribution of infants in relation to GA and BW.
Years

Number of
examined infants

Number of
treated infants

% of treated
infants

Mean GA ± SD
(min–max) (weeks)

Mean BW ± SD
(min–max) (g)

2006

927

32

3.5

28.8 ± 1.9
(26–32)

1231.2 ± 277.9
(900–1900)

2007

1056

26

2.5

28.8 ± 2.4
(26–33)

1265.0 ± 306.9
(850–1850)

2008

1027

34

3.3

27.8 ± 1.6
(26–31)

1047.6 ± 289.2
(760–1770)

2009

1117

132

11.8

27.5 ± 2.1
(24–32)

980.4 ± 263.7
(510–2030)

2010

1132

100

8.8

27.1 ± 2.6
(22–32)

926.5 ± 254.0
(550–1600)

2011

1237

74

6.0

26.5 ± 2.4
(23–33)

912.3 ± 245.1
(630–1700)

2012

1241

64

5.2

26.6 ± 2.3
(24–33)

978.7 ± 349.4
(520–1900)

2013

1271

94

7.4

26.9 ± 2.9
(22–33)

973.4 ± 409.8
(560–2160)

Total

9008

556

6.2

27.3 ± 2.5
(22–33)

991.1 ± 314.7
(510–2160)

old at the time of laser therapy and all except one were in
Group 2. Ten of these later-treated babies were treated at
43 PM weeks and only 1 infant in Group 2 was treated at
48 PM weeks.
The mean BW and the mean GA were significantly
higher in Group 2 and the mean postnatal age at the time
of laser therapy was significantly earlier in Group 2. The
PM age at the time of laser therapy did not differ between
the two groups (Table 4).
4. Discussion
A third epidemic of ROP is now being experienced in
developing countries with high preterm birth rates,
where babies are exposed to risk factors that are largely
well controlled in developed countries. Affected babies
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have a wider range of BWs and GAs compared to those
from developed countries. There are great differences in
the standard of care even in different neonatal intensive
care units in the same country. Population-specific or
even institution-specific criteria should be established
for ROP screening to minimize the number of infants
screened while missing no patient with ROP who requires
treatment (1,9–15). Recent studies from Turkey indicated
that first we need a national guideline for ROP screening
and then we should discuss institution-specific screening
criteria (1,9,15–17).
Our hospital, which has the largest neonatal intensive
care unit in Turkey, is the referral center for central, east,
and north Anatolia for high-risk pregnancies and preterm
births, and our clinic is the ROP referral center for high-risk

ÖZEN TUNAY et al. / Turk J Med Sci
Table 4. Comparisons of clinical features between the groups.
Group 1
(n = 396)

Group 2
(n = 160)

*P

Birth weight (g) (mean ± SD)

941.4 ± 276.6

1111.9 ± 366.0

0.001

Gestational age (weeks) (mean ± SD)

26.9 ± 2.3

28.2 ± 2.6

0.001

Postnatal age at the time of laser therapy (weeks) (mean ± SD)

9.8 ± 2.7

8.8 ± 3.0

0.001

Postmenstrual age at the time of laser therapy (weeks) (mean ± SD)

36.6 ± 2.8

36.9 ± 2.9

0.227

Group 1: Infants who were born in our hospital and received treatment for ROP in our hospital.
Group 2: Infants who were born at different centers and referred to our hospital for ROP treatment.
*: Independent samples t-test.

premature infants. In our study group, treatment-requiring
severe ROP was determined in 6.2% of the overall infants
and 4.5% in Group 1. In the previous studies from our
country, the rates of severe ROP were 3.1%–11.5% (1,13–
22). Our present study has the largest sample size among
them and the study period was much longer. When we
compared percentages with the data from other countries,
we observed that our results were more compatible with
the data from developed countries, but the BWs and GAs
of screened infants were not the same in each study group.
The incidence of treatment-requiring severe ROP has been
reported as 1.8%–8.3% in the Netherlands, 1.3%–7.8% in
the United States, 6.8% in China, 9.5% in Iran, 4.9% in
Taiwan, 11.7% in Romania, 5.8% in Brazil, 6.4% in Saudi
Arabia, and 6.7% in India (9–12,23–27).
We saw more infants requiring laser treatment in 2009
and 2010. Because our clinic was labeled a ROP referral
and training center by the Ministry of Health in 2009,
the numbers of Group 2 infants were higher in 2009 and
2010. Approximately two-thirds of the treated infants were
referred from other hospitals in these years. After 2010,
the number of ROP referral and training centers in Turkey
increased, so the number of infants referred to our clinic
began to decline.
It has been presented that the mean BW of infants
with severe ROP is 750 g in developed countries and 1500
g in developing countries. Recent data from the United
States, the United Kingdom, and Canada show that infants
requiring treatment for ROP have a mean BW of 736 g
(415–1255 g), 737 g (450–1260 g), and 759 g (440–1785
g) and a mean GA of 25.4 (23–29), 25.3 (23–32), and 25.6
weeks (22–32), respectively (28). Populations of babies
with ROP in low- and middle-income countries are
quite different from populations studied in high-income
countries. Karkhaneh et al. from Iran reported that the
frequency of severe ROP was 22.5% among babies who
were born before 37 weeks’ GA and that babies with severe
ROP had a mean GA of 28.8 ± 2.2 weeks and a mean BW of

1257 ± 348 g (29). In a multicenter study from China, the
incidence of treatment-requiring ROP was 3.6% among
babies with BWs less than 2000 g or GAs younger than 35
weeks; mean GAs and BWs of those babies were 30.2 ± 2.1
weeks and 1273.9 ± 263.5 g, respectively (30). In another
study from Hong Kong, the incidence of Type 1 ROP in
extremely low birth weight infants was 14.5% (31). In the
present study, the mean GA of treated infants was 27.3
± 2.5 weeks (22–33 weeks) and the mean BW was 991.1
± 314.7 g (520–2160 g). These values were between the
values of the industrialized countries and the developing
countries and slightly better than the other developing
countries (23–27).
As the years go by, we encounter smaller and more
prematurely born infants with severe ROP, but we still
continue to see treatment-requiring ROP in infants with
BWs over 1500 g. Of the 556 treated babies, 7.4% had
GAs over 31 weeks, but no infant had a GA greater than
33 weeks. Out of the treated infants, 8.3% had BWs over
1500 g; the highest BW of an infant with severe ROP was
2160 g. Mutlu et al. reported that the percentage of infants
with BWs greater than 1500 g treated for ROP was 9.1%
(15). In other studies from Turkey, while Sarikabadayi et
al. and Alpay et al. reported that no infant born at a GA of
older than 32 weeks needed treatment for ROP, Ugurbas
et al. and Başmak et al. reported that the percentage of
treated babies among infants born at a GA of 32 weeks or
older was 9.6% and 9.3%, respectively (1,14,20,21). Similar
findings were reported in studies from China, India,
Iran, Saudi Arabia, Taiwan, Brazil, and Turkey, and it was
recommended that larger infants be included in screening
programs to avoid missing cases (9,10,17,24–27).
Globally, 6.2% (4.3%–8.9%) of all ROP visually
impaired infants were born at a GA of 32 weeks (9). Several
studies have shown that the screening criteria of developed
countries are not adequate to identify all infants at risk
of severe ROP requiring treatment in low- and middleincome countries (24–27). Gilbert et al. found that, overall,
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13% of infants from several low- and middle-income
countries would not have been examined if UK criteria
had been applied (28). In China, Chen et al. showed that
16% of infants who needed treatment exceeded the UK
criteria and 30% exceeded the US criteria (30). Jalali et al.
from India reported that 13% of treated infants exceeded
the US criteria (32). A study from Brazil confirmed that
wider criteria were needed as well; 11% of treated infants
exceeded the Western screening criteria (27).
In previous studies, it was reported that treatment for
severe ROP was rarely required before 31 PM weeks. Mean
PM age for treatment in high-income settings is 35.2 weeks
(30.6–42.1 weeks) (8). Treatment might be carried out up
to 51 PM weeks in some low-income settings because of
delayed case detection (9). In the present study, the mean
PM age at the time of treatment was 36.72 ± 2.83 weeks
and it ranged between 29 and 48 weeks. This mean value
is compatible with high-income settings, but the range of
PM ages in our study group were as wide as in low-income
settings.
The recommended time for the initial ROP examination
is 4–6 postnatal weeks or 31 PM weeks in high-income
settings (5–7). In this study, the treatments for ROP were
required at 5 postnatal weeks in 14 infants (2.5%) and at
6 postnatal weeks in 66 (11.9%) infants. For four infants,
treatments were needed before 31 PM weeks. We suggest
that ROP screening programs should start at 4 postnatal
weeks and not later than 5 postnatal weeks. It should not
be postponed until 31 PM weeks because of infants who
need treatment at an earlier age.

When we compared the infants in Group 1 and Group
2, we determined that the mean BW and the mean GA were
significantly higher in Group 2 and the mean postnatal
ages at the time of laser therapy were significantly younger
in Group 2. These results may be related to unstandardized
conditions of the neonatal intensive care units, such as
unstandardized oxygen supplementation levels and the
number of babies per nurse and per doctor (1,4,8,33–36).
To evaluate these differences, future studies with expanded
risk factors should be planned.
A major limitation of this long-term study was being
based in a single center, but approximately 30% of the babies
were infants referred from different neonatal intensive
care units all over our country. We need multicenter trials
to create a national ROP screening guideline. We believe
that our long-term study, with its large number of infants,
can contribute to this guideline.
This study has shown that larger infants in our
country may need treatment for ROP. When we analyzed
GA independently from other risk factors, no treatment
was required for babies born at a GA of over 33 weeks.
Treatment for ROP may be needed before 31 PM weeks and
before 6 postnatal weeks for some premature babies. The
screening criteria must be individualized for our country
and a national guideline must be created for ROP screening
with the guidance of large series and multicenter trials. A
future prospective study with expanded screening criteria
was planned to help create the national screening criteria.
Screening the infants most at risk and timely treatment for
ROP that progresses to a sight-threatening level must be the
standard care to prevent serious visual disability.
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